atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
Exceptional clinical leadership in the 21st century demands strong communication skills and the ability to listen to colleagues. Effective leadership necessitates a cultural shift within organisations, fostering openness and innovation.
Catch up on insightful discussions from the expert panel featuring…
Congratulations on the launch of "Every Dose Used-Reducing Wasted Medicines Playbook" co-authored by Deloitte & @YewMaker on behalf of the Sustainable Medicines Partnership. Download the report here.